PMID- 3473163
OWN - NLM
STAT- MEDLINE
DCOM- 19870707
LR  - 20131121
IS  - 0025-7850 (Print)
IS  - 0025-7850 (Linking)
VI  - 17
IP  - 3-4
DP  - 1986
TI  - Tumor immunoglobulin with antibody activity against blood coagulation factors.
PG  - 149-65
AB  - A cultured tumor cell line from the Greene lymphoma was shown in vitro to secrete 
      immunoglobins of the IgG2 subclass (TcIg), which possessed a direct inhibiting 
      effect on blood coagulation. TcIg prolonged the thrombin time (TT) of normal 
      hamster plasma in vitro. Moreover, the effect of heparin which prolonged the 
      plasma thrombin time was reinforced when TcIg was added to the test. This 
      property was not neutralized by protamine sulfate. In the plasma kaolin clotting 
      time test (KCT), the addition of TcIg lead to an anticoagulant effect, but weaker 
      than in TT. The mixing pattern of normal plasma with tumor-bearing hamster plasma 
      did not reveal the presence of circulating inhibitor in tumor plasma. It was 
      suggested that TcIg had heparin-like activity.
FAU - Antonucci, M
AU  - Antonucci M
FAU - Berard, M
AU  - Berard M
FAU - Beaumont, J L
AU  - Beaumont JL
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Med
JT  - Journal of medicine
JID - 7505566
RN  - 0 (Antibodies, Neoplasm)
RN  - 0 (Blood Coagulation Factors)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Protamines)
RN  - 24H4NWX5CO (Kaolin)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Animals
MH  - Antibodies, Neoplasm/*analysis
MH  - Blood Coagulation
MH  - Blood Coagulation Factors/*immunology
MH  - Cell Line
MH  - Cricetinae
MH  - Heparin/pharmacology
MH  - Hydrogen-Ion Concentration
MH  - Immunoglobulin G/classification/*immunology/isolation & purification
MH  - Kaolin/pharmacology
MH  - Lymphoma/*immunology
MH  - Protamines/pharmacology
MH  - Thrombin Time
EDAT- 1986/01/01 00:00
MHDA- 1986/01/01 00:01
CRDT- 1986/01/01 00:00
PHST- 1986/01/01 00:00 [pubmed]
PHST- 1986/01/01 00:01 [medline]
PHST- 1986/01/01 00:00 [entrez]
PST - ppublish
SO  - J Med. 1986;17(3-4):149-65.